William Blair & Company
OVID icon

William Blair & Company’s Ovid Therapeutics OVID Stock Holding History

William Blair & Company’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64K Buy
28,839
+2,500
+9% +$4.47K ﹤0.01% 1661
2025
Q4 		$42.9K Buy
26,339
+1,250
+5% +$1.93K ﹤0.01% 1671
2025
Q3 		$32.6K Buy
25,089
+3,000
+14% +$2.6K ﹤0.01% 1683
2025
Q2 		$7.29K Sell
22,089
-950
-4% -$286 ﹤0.01% 1752
2025
Q1 		$7.19K Hold
23,039
– – ﹤0.01% 1734
2024
Q4 		$21.5K Sell
23,039
-9,000
-28% -$10.1K ﹤0.01% 1683
2024
Q3 		$37.8K Buy
32,039
+1,000
+3% +$1.04K ﹤0.01% 1662
2024
Q2 		$23.9K Buy
31,039
+7,100
+30% +$19.8K ﹤0.01% 1677
2024
Q1 		$73K Buy
23,939
+2,263
+10% +$7.57K ﹤0.01% 1552
2023
Q4 		$69.8K Sell
21,676
-401
-2% -$1.37K ﹤0.01% 1550
2023
Q3 		$84.8K Sell
22,077
-1,250
-5% -$4.49K ﹤0.01% 1525
2023
Q2 		$76.5K Sell
23,327
-1,001
-4% -$3.4K ﹤0.01% 1545
2023
Q1 		$62.8K Hold
24,328
– – ﹤0.01% 1552
2022
Q4 		$45.3K Sell
24,328
-6,900
-22% -$11.8K ﹤0.01% 1588
2022
Q3 		$57K Hold
31,228
– – ﹤0.01% 1582
2022
Q2 		$67K Sell
31,228
-27,137
-46% -$65.6K ﹤0.01% 1590
2022
Q1 		$183K Sell
58,365
-32,487
-36% -$102K ﹤0.01% 1540
2021
Q4 		$292K Sell
90,852
-6,146
-6% -$21.1K ﹤0.01% 1435
2021
Q3 		$326K Sell
96,998
-19,762
-17% -$72.1K ﹤0.01% 1315
2021
Q2 		$457K Sell
116,760
-39,722
-25% -$157K ﹤0.01% 1177
2021
Q1 		$629K Buy
156,482
+18,822
+14% +$62.5K ﹤0.01% 1050
2020
Q4 		$318K Sell
137,660
-27,076
-16% -$126K ﹤0.01% 1240
2020
Q3 		$946K Buy
164,736
+87,180
+112% +$583K ﹤0.01% 772
2020
Q2 		$572K Buy
77,556
+12,556
+19% +$58.7K ﹤0.01% 896
2020
Q1 		$194K Sell
65,000
-125,253
-66% -$422K ﹤0.01% 1174
2019
Q4 		$790K Buy
+190,253
New +$601K ﹤0.01% 846

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

William Blair & Company's OVID Position: Q1 2026 in Review

William Blair & Company increased its Ovid Therapeutics (OVID) stake by 9.5% in Q1 2026, buying an estimated $4.47K and bringing the position to 28,839 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

William Blair & Company first reported a position in OVID in Q4 2019 and has held it in 26 quarters since. The position peaked at $946K in Q3 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • William Blair & Company held 28,839 shares of Ovid Therapeutics worth $64K as of Q1 2026.
  • William Blair & Company bought 2,500 Ovid Therapeutics shares in Q1 2026, an estimated $4.47K.
  • Ovid Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1661 holding.
  • William Blair & Company first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • William Blair & Company's Ovid Therapeutics position peaked at $946K in Q3 2020.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.